| Using HAQ-DI to estimate HUI-3 and EQ-5D utility values for patients with rheumatoid arthritis in Spain. | |
| | |
MedLine Citation:
|
PMID: 21211502 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
BACKGROUND/OBJECTIVE: Utility values are not usually assessed in clinical trials and do not allow cost-utility analysis to be performed with the data collected. The aim of this study was to derive relation functions so that Health Assessment Questionnaire - Disability Index (HAQ-DI) scores could be used to estimate Health Utilities Index - 3 (HUI-3) and EQ-5D utility values for patients with rheumatoid arthritis (RA). METHODS: An observational, cross-sectional, naturalistic, multicentre study was conducted. A total of 244 patients aged 18 years or older, with RA according to American College of Rheumatology diagnostic criteria, were recruited. Sociodemographic and clinical variables were recorded and patients completed three generic HRQoL questionnaires: the HAQ-DI, the HUI-3, and the EQ-5D. Two linear regression models were used to predict HUI-3 and EQ-5D utility values as functions of HAQ-DI scores, age, and gender. RESULTS: Patient mean age was 57.8 years old (standard deviation [SD], 13.3 years); 75.8% of the patients were women and 95.9% were white. Mean disease duration was 10.8 years (SD, 9 years). Patient distribution according to HAQ-DI severity was as follows: HAQ-DI < 0.5, 29%; 0.5 ≤ HAQ-DI < 1.1, 28%; 1.1 ≤ HAQ-DI < 1.6, 16%,1.6 ≤ HAQ-DI < 2.1, 15%; and HAQ-DI ≥ 2.1, 12%. HAQ-DI and EQ-5D mean scores were 1.02 (SD, 0.78) and 63.1 (SD, 20.3), respectively. Mean utility values for HUI-3 and time trade-off (TTO) were 0.75 (SD, 0.21) and 0.65 (SD, 0.3), respectively. The equations converting HAQ-DI scores to utilities were HUI-3 = 0.9527 - (0.2018 × HAQ-DI) +ε (R(2)=0.56), and TTO = 0.9567 - (0.309 × HAQ-DI) + ε (R(2)=0.54). Error distribution was non-normal. Age and gender were found to have no bearing on the utility functions. CONCLUSIONS: HAQ-DI scores can be used to estimate HUI-3 and EQ-5D utility values for patients with RA in data obtained from studies where utility values have not been collected. |
| | |
Authors:
|
Agata Carreño; Ignacio Fernández; Xavier Badia; Cristina Varela; Montserrat Roset |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research Volume: 14 ISSN: 1524-4733 ISO Abbreviation: Value Health Publication Date: 2011 Jan |
Date Detail:
|
Created Date: 2011-01-07 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 100883818 Medline TA: Value Health Country: United States |
Other Details:
|
Languages: eng Pagination: 192-200 Citation Subset: IM |
Copyright Information:
|
Copyright © 2011 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc. All rights reserved. |
Affiliation:
|
Health Economics and Outcomes Research - IMS Health, Barcelona, Spain. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Impact of ACE inhibitors on mortality and morbidity in patients with AMI: Does tissue selectivity ma...
Next Document: Synergism between wild-type Bacillus thuringiensis subsp. israelensis and B. sphaericus strains: A s...